Ascendis’ Hypoparathyrodism Drug Secures FDA Approval Following Tough Regulatory Path

Ascendis Pharma’s palopegteriparatide was previously rejected by the regulator due to manufacturing problems, and the review period for its resubmitted application was extended by three months.